| Autor: |
Ronson J. Madathil, Geoffrey L. Rosenthal, Allen D. Everett, Karakeshishyan, Desire Y, Lina V. Caceres, Matthew N. Klein, Ali Ghodsizad, Matthias Loebe, Derek K. Ng, Dushyantha Jayaweera, Kristopher B. Deatrick, Abhinandan Khan, Bangon Longsomboon, Sunjay Kaushal, Zhu J, Joshua M. Hare, Magali J. Fontaine, Sixto Arias, Rachana Mishra, Lamazares R, Melania M. Bembea, Russell G. Saltzman, Atala A, Snyder A, Ketty Bacallao, Muthukumar Gunasekaran, Aakash Shah, Adriana E. Brooks, Ayoade F, Jairo A. Tovar, Kristin E. Mullins, David J. Kaczorowski, Ali Tabatabai, Progyaparamita Saha, G.Hankey K, Hayley B. Gershengorn |
| Rok vydání: |
2020 |
| Předmět: |
|
| DOI: |
10.1101/2020.10.15.20122523 |
| Popis: |
BackgroundThere is an ongoing critical need to improve therapeutic strategies for COVID-19 pneumonia, particularly in the most severely affected patients. Adult mesenchymal stem cell (MSC) infusions have the potential to benefit critically ill patients with acute respiratory syndrome SARS-COV-2 infection, but clinical data supporting efficacy are lacking.MethodsWe conducted a case-control study of critically ill patients with laboratory-confirmed COVID-19, severe acute respiratory distress syndrome (ARDS). To evaluate clinical responsiveness in the most critically ill patient we examined outcomes in a sub-group of those requiring extracorporeal membrane oxygenation (ECMO) support. Patients (n=9) were administered with up to 3 infusions of intravenous (IV) MSCs and compared to a local ECMO control group (n=31). The primary outcome was safety, and the secondary outcomes were all-cause mortality (or rate of hospital discharge), cytokine levels, and viral clearance.FindingsMSC infusions (12 patients) were well tolerated and no side effects occurred. Of ECMO patients receiving MSC infusions, 2 out of 9 died (22.2%; 95%CI: 2.8%, 60.0%) compared with a mortality of 15 of 31 (48.4%; 95%CI: 30.2%, 66.9%; p = 0.25) in the ECMO control group. Isolated plasma exosomes containing the SARS-COV-2 Spike protein decreased after MSC infusions between day 14 or 21 after administration (p=0.003 and p=0.005, respectively) and was associated with a decrease in COVID-19 IgG Spike protein titer at same time points (p = 0.006 and p=0.007, respectively). Control ECMO patients receiving convalescent plasma did not clear COVID-19 IgG over the same time frame.InterpretationTogether these findings suggest that MSC IV infusion is well tolerated in patients with a broad range of severity including the most severe COVID-19 ARDS requiring ECMO. These data also raise the possibility that MSCs, in addition to exerting an immunomodulatory effect, contribute to viral clearance and strongly support the conduct of randomized placebo-controlled trial. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
